{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107419","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.227817+00:00","generated_at":"2026-05-16T23:49:46.109387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026","bullets":["Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.","R&D expense $37.5M (up $3.9M QoQ) driven by EDG-15400 Phase 1 start and CIRRUS-HCM activity.","Net loss $40.7M ($0.39 per share) vs $36.1M ($0.34) prior quarter.","GRAND CANYON pivotal Becker cohort (175 enrolled) on track for topline readout in Q4 2026.","EDG-7500 CIRRUS-HCM program update expected Q4 2025; EDG-15400 Phase 1 data H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107419","json":"https://secwatch.observer/filing/0001104659-25-107419.json","markdown":"https://secwatch.observer/filing/0001104659-25-107419.md","text":"https://secwatch.observer/filing/0001104659-25-107419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/0001104659-25-107419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/tm2529979d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:49:46.109387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}